Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States.
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States.
Cancer Lett. 2021 Apr 10;503:11-18. doi: 10.1016/j.canlet.2021.01.010. Epub 2021 Jan 20.
The hexosamine biosynthetic pathway (HBP) is a glucose metabolism pathway that results in the synthesis of a nucleotide sugar UDP-GlcNAc, which is subsequently used for the post-translational modification (O-GlcNAcylation) of intracellular proteins that regulate nutrient sensing and stress response. The HBP is carried out by a series of enzymes, many of which have been extensively implicated in cancer pathophysiology. Increasing evidence suggests that elevated activation of the HBP may act as a cancer biomarker. Inhibition of HBP enzymes could suppress tumor cell growth, modulate the immune response, reduce resistance, and sensitize tumor cells to conventional cancer therapy. Therefore, targeting the HBP may serve as a novel strategy for treating cancer patients. Here, we review the current findings on the significance of HBP enzymes in various cancers and discuss future approaches for exploiting HBP inhibition for cancer treatment.
己糖胺生物合成途径（HBP）是一种葡萄糖代谢途径，导致核苷酸糖 UDP-GlcNAc 的合成，随后用于调节营养感应和应激反应的细胞内蛋白质的翻译后修饰（O-GlcNAcylation）。HBP 由一系列酶进行，其中许多酶已广泛涉及癌症病理生理学。越来越多的证据表明，HBP 的激活升高可能作为癌症生物标志物。HBP 酶的抑制可以抑制肿瘤细胞生长，调节免疫反应，降低耐药性，并使肿瘤细胞对常规癌症治疗敏感。因此，靶向 HBP 可能是治疗癌症患者的一种新策略。在这里，我们综述了 HBP 酶在各种癌症中的重要性的最新发现，并讨论了利用 HBP 抑制治疗癌症的未来方法。
